pentobarbital will lower the extent or effect of saxagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lower the level or impact of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will lessen the extent or impact of clarithromycin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
pentobarbital will reduce the level or impact of pitolisant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Pitolisant exposure is reduced by 50% if coadministered with powerful CYP3A4 inducers.
Consistently keep an eye on important indications all through sedation and recovery period if coadministered. Meticulously titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
Contraindicated (one)pentobarbital will lessen the extent or influence of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Women mustn't select estradiol valerate/dienogest as their contraceptive though utilizing potent CYP3A4 inducers because of potential decrease in contraceptive efficacy.
Contraindicated (1)pentobarbital decreases levels of panobinostat by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can decrease panobinostat amounts by ~70% and produce treatment failure.
pentobarbital will decrease the extent or influence of dutasteride by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
pentobarbital will decrease the level or effect of piroxicam website by affecting hepatic enzyme CYP2C9/ten metabolism. Insignificant/Importance Unfamiliar.
Reserve concomitant prescribing of such drugs in individuals for whom other treatment method solutions are insufficient. Restrict dosages and durations towards the minimum amount expected. Check carefully for signs of respiratory despair and sedation.
Contraindicated (1)pentobarbital will lower the extent or influence of lorlatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or outcome of loratadine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lessen the extent or influence of nimodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will reduce the level or outcome of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.